|Name of Journal||Artificial Intelligence in Cancer|
|Title Abbreviation||Artif Intell Cancer|
|Background||Artificial Intelligence in Cancer (AIC, Artif Intell Cancer) is a high-quality, online, open-access, single-blind peer-reviewed journal published by the Baishideng Publishing Group (BPG). AIC accepts both solicited and unsolicited manuscripts. Articles published in AIC are high-quality, basic and clinical, influential research articles by established academic authors as well as new researchers. The paramount objective of AIC is to showcase and promote distinguished research in the field of artificial intelligence in cancer, to help advance development of this field. The types of articles published in the AIC include Editorial, Opinion Review, Frontier, Review, Minireview, Basic Study, Clinical Research, Systematic Review, Meta-analysis, Evidence-based Medicine, Field of Vision, Clinical Guidelines, Letter to the Editor, and Case Report.|
The primary aim of AIC is to provide scholars and readers from various fields of artificial intelligence in cancer with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. In order to ensure the quality, timeliness, fairness, and transparency of publication, AIC has implemented a variety of measures as follows:
First, authors must prepare their articles according to the appropriate international publication recommendations, including the STROBE Statement, CONSORT 2010 Statement, PRISMA 2009 Checklist, and CARE Checklist – 2016: Information for writing a case report.
Second, articles published in AIC must undergo rigorous cross-international peer review. AIC peer reviewers come from different countries, chosen independently by artificial intelligence technique or our editorial office, and not by the authors, to ensure fairness and integrity of the peer review.
Third, designation of co-first authors and/or co-corresponding authors is not permitted.
Fourth, AIC accepts a manuscript for publication based on its novelty, innovativeness, data accuracy, image reliability, clear language expression, and ethical requirements.
Of note, peer reviewers are advised to complete their peer review within 7 days, providing a comprehensive evaluation of the scientific and linguistic quality of the manuscript.
Fifth, BPG adopts a 7-day publishing management policy. This means that each step of the publishing process, including manuscript preview, peer review, manuscript revision by authors, final acceptance, language editing, and production, and release, must be completed within 7 days.
Finally, the peer review report, author’s response to the peer review report, biostatistics review certificate, copyright license agreement, institutional ethics committee approval document, informed consent document(s), conflict-of-interest statement, CrossCheck detection report, authors’ personal ORCID numbers, funding information, language editing certificate, and other relevant documents will be published online along with the article to allow for an open and transparent publishing process.
|Scope||AIC mainly publishes articles reporting research results obtained in the field of artificial intelligence in cancer and covering a wide range of topics, including artificial intelligence in bone oncology, breast cancer, gastrointestinal cancer, genitourinary cancer, gynecological cancer, head and neck cancer, hematologic malignancy, lung cancer, lymphoma and myeloma, pediatric oncology, and urologic oncology.|
|Open Access||Open access|
There is currently no indexing.
There is currently no impact factor.
|Article Processing Charge||Article processing charge|
|Editors-in-Chief||Cedric Coulouarn, Mujib Ullah|
|Article Reprints||Article reprints|
|Help Desk||Help desk|
|Special Statement||Special statement|
|Copyright ©||© 2004-2020 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA|
|Contact Us||Contact us|